



February 2012

Volume 17 Numbers 3/4
pp. 97–182



Cover Story

The leading story of this issue of Drug Discovery Today, by Wenni Tong and Lubo Zhang summarizes current knowledge of the mechanisms by which fetal hypoxia induces the imbalance of MMPs, TIMPs and collagen expression patterns, resulting in growth restriction and aberrant tissue remodeling in the developing heart and brain. Collectively, this information could lead to the development of preventive diagnoses and therapeutic strategies in the fetal programming of cardiovascular and neurological disorders.

DRUG DISCOVERY TODAY

REVIEWS

FOUNDATION

110 **Foundation review: MRI as a tool for evaluation of oral controlled release dosage forms**

Przemysław P. Dorożyński, Piotr Kulinowski, Anna Młynarczyk and Greg J. Stanisz

KEYNOTE

124 **Fetal hypoxia and programming of matrix metalloproteinases**

Wenni Tong and Lubo Zhang

INFORMATICS

135 **The value of *in silico* chemistry in the safety assessment of chemicals in the consumer goods and pharmaceutical industries**

Sandeep Modi, Michael Hughes, Andrew Garrow and Andrew White

POST SCREEN

143 **Mesopore-assisted profiling strategies in clinical proteomics for drug/target discovery**

Rocco Savino and Rosa Terracciano

153 **The formulation of polyhedral boranes for the boron neutron capture therapy of cancer**

Gianpiero Calabrese, John J. Nesnas, Eugen Barbu, Dimitris Fatouros and John Tsibouklis

160 **Liposomal drug formulations in cancer therapy: 15 years along the road**

Marije Slingerland, Henk-Jan Guchelaar and Hans Gelderblom

167 **Rare disease patient groups as clinical researchers**

Ginger R. Polich

173 **Biomimetic tissues on a chip for drug discovery**

Amir M. Ghaemmaghami, Matthew J. Hancock, Helen Harrington, Hirokazu Kaji and Ali Khademhosseini